BI 811283

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BI 811283, covering 2014-07-22 to 2015-05-25. Get the full timeline:

Most recent: Clinical Trial Update: BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment [Phase 2]